Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
Items 401–500 of 1,000
Recent Science and Clinical Application of Nutrition to Coronary Heart Disease
Houston, M. C., Minich, D. M., Sinatra, S. T., Kahn, J. K., & Guarneri, M. (2018) · Journal of the American College of Nutrition · doi:10.1080/07315724.2017.1381053 · Cited by 25
Multidisciplinary Approach to Management and Care of Patients with Type 2 Diabetes Mellitus
Bain, S., Cummings, M. H., & McKay, G. A. (2019) · EMJ Diabetes · doi:10.33590/emjdiabet/10314374 · Cited by 22
Klempfner, R., Elis, A., Matezky, S., Keren, G., Roth, A., Finkelstein, A., Banai, S., Goldenberg, I., Fisman, E. Z., Tenenbaum, A., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.116 · Cited by 24
Advances in use of immunomodulatory agents—a rheumatology perspective
Her, M., & Kavanaugh, A. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.65 · Cited by 24
Neugebauer, R. S., Schroeder, E. B., Reynolds, K., Schmittdiel, J. A., Loes, L., Dyer, W., DESAI, J. R., Vazquez‐Benitez, G., Ho, P. M., Anderson, J. P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18554 · Cited by 22
DeRemer, C. E., Vouri, S. M., Guo, J. S., Donahoo, W. T., Winterstein, A. G., & Shao, H. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107972 · Cited by 24
Sanz, J., Moreno, P., & Fuster, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.045 · Cited by 26
“etes for CVD protection (ACCORD study and others) (91,93).”
BackgroundTherapeutic strategies targeting mechanisms of macrophages in diabetic heart disease
Zhang, C., Shi, Y., Liu, C., Sudesh, S. M., Zhao, H., Li, P., Liu, Q., Ma, Y., Shi, A., & Cai, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02273-4 · Cited by 32
Szwergold, B. S., & Miller, C. B. (2014) · Rejuvenation Research · doi:10.1089/rej.2014.1561 · Cited by 24
Calderón‐Larrañaga, A., Soljak, M., Cecil, E. V., Valabhji, J., Bell, D., Prados‐Torres, A., & Majeed, A. (2014) · Diabetic Medicine · doi:10.1111/dme.12413 · Cited by 29
Brod, M. I., Wolden, M. L., Groleau, D., & Bushnell, D. M. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.857676 · Cited by 25
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
Verbrugge, F. H. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0340-1 · Cited by 25
dʼEmden, M. C., Amerena, J. V., Deed, G., Pollock, C. A., & Cooper, M. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.023 · Cited by 27
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
“5% or lower for diabetic hypertensive patients is from the combined analysis of the ACCORD-BP and ACCORD study.(32) In this 2 2 factorial analysis stratified by both intensive versus standard BP and glucose control strategies, it has been demonstrated that the increased mortality associated with targeting HbA1c of <6%…”
BackgroundStrategies to Prioritize Clinical Options in Primary Care
O’Connor, P. J., Sperl‐Hillen, J. M., Margolis, K. L., & Kottke, T. E. (2017) · The Annals of Family Medicine · doi:10.1370/afm.2027 · Cited by 24
Zeng, C. C., Liu, M., Zhang, Y., Deng, S., Xin, Y., & Hu, X. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad645 · Cited by 30
Supervised exercise therapy for intermittent claudication: current status and future perspectives
Lauret, G.-J., van Dalen, D. C. W., Willigendael, E. M., Hendriks, E., de Bie, R. A., Spronk, S., & Teijink, J. A. W. (2012) · Vascular · doi:10.1258/vasc.2011.ra0052 · Cited by 24
How do high glycemic load diets influence coronary heart disease?
Mathews, M. J., Liebenberg, L., & Mathews, E. H. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0001-x · Cited by 26
“55 [45-53,105-110] 56 [45,54-57] 57 [45,54-57,93,111-114] 58 [45,54-57,93] 59 [82-85] 60 [82-85]”
Neugebauer, R. S., FIREMAN, B. H., Roy, J. A., & O’Connor, P. J. (2013) · Diabetes Care · doi:10.2337/dc12-2675 · Cited by 23
Carotid atherosclerosis progression and cerebrovascular events in patients with diabetes
Vouillarmet, J., Helfre, M., Maucort‐Boulch, D., Riche, B., Thivolet, C. H., & Grangé, C. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.022 · Cited by 22
Kim, A., Gwon, M.-H., Lee, W., Moon, H.-R., & Yun, J. (2022) · Nutrition Research · doi:10.1016/j.nutres.2022.01.002 · Cited by 22
A Look Ahead at the Future of Diabetes Prevention and Treatment
Arterburn, D. E., & O’Connor, P. J. (2012) · JAMA · doi:10.1001/jama.2012.144749 · Cited by 22
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
“Severe hypoglycemia is strongly associated with an increased risk of macro-and microvascular events, and death in people with T2D [114, 115].”
Boukhris, M., Tomasello, S. D., Khanfir, R., Elhadj, Z. I., Terra, A. W., Marzà, F., Azzarelli, S. A., Galassi, A. R., & Boukhris, B. (2015) · Heart & Lung · doi:10.1016/j.hrtlng.2015.02.003 · Cited by 20
Milligan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.010 · Cited by 23
“The ACCORD trial was discontinued prematurely because of an increased risk of all-cause mortality (hazard ratio [HR], 1.22 [95% CI 1.01, 1.46]; P = 0.04) in the intensive versus standard-therapy arm (Gerstein et al., 2008).”
MethodInfluentialXu, Y., Murphy, A. J., & Fleetwood, A. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042234 · Cited by 23
“The persistent risk of cardiovascular complications, even after lowering glucose, has been termed “hyperglycemic memory” [62].”
BackgroundShah, H., McGill, J. B., Hirsch, I. B., Wu, C.-Y., Gałecki, A. T., de Boer, I. H., Mauer, M. S., & Doria, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae044 · Cited by 24
Abdul-Ghani, M., Williams, K., Kanat, M., Altuntaş, Y., & DeFronzo, R. (2013) · Journal of Endocrinological Investigation · doi:10.3275/8367 · Cited by 22
Sun, H. Q., Zhao, Y., Bi, X., Li, S., Su, G., Miao, Y., Ma, X., Zhang, Y., Zhang, W., & Zhong, M. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0246-8 · Cited by 20
“Thus, activation of a TSP1-mediated TGFβ1/Smads pathway plays an important role in marcovascular remodeling in T2DM, and valsartan may hold promise for blocking the pathway and ameliorating vascular fibrosis in diabetes.”
BackgroundInfluentialInsulin Therapy and Cancer in Type 2 Diabetes
Mannucci, E. (2012) · ISRN Endocrinology · doi:10.5402/2012/240634 · Cited by 26
“Despite this fact, cancer-related mortality in the ACCORD trial was similar in the two arms [62], even in the longer-term (5-year) followup [65].”
BackgroundSerikawa, T., Miura, S., Okabe, M., Hongo, H., Tokutome, M., Yoshikawa, T., Takesue, K., Adachi, S., Osaka, K., Matsukawa, R., et al. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.06.016 · Cited by 23
The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes
Paty, B. W. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.009 · Cited by 26
Managing Hypertension in Patients with CKD
Chertow, G. M., Beddhu, S., Lewis, J. B., Toto, R. D., & Cheung, A. K. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015101125 · Cited by 20
Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
Rydén, L., Shahim, B., & Mellbin, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.035 · Cited by 21
Matsuura, Y., Yamashita, A., Zhao, Y., Iwakiri, T., Yamasaki, K., Sugita, C., Koshimoto, C., Kitamura, K., Kawai, K., Tamaki, N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175976 · Cited by 20
Derivation and validation model for hospital hypoglycemia
Ena, J., Gaviria, A. Z., Romero-Sánchez, M., Carretero‐Gómez, J., Carrasco-Sánchez, F. J., Segura, J., Porto-Pérez, A. B., Vázquez-Rodríguez, P., González-Becerra, C., & Gómez‐Huelgas, R. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.024 · Cited by 20
Decision models in type 2 diabetes mellitus: A systematic review
Li, J., Bao, Y., Chen, X., & Tian, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01742-6 · Cited by 25
Kang, E. Y., Kang, C., Wu, W., Sun, C., Chen, K., Lai, C., Chen, T., & Hwang, Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132871 · Cited by 20
“lowering reduced the risk of cardiovascular diseases, microvascular complications, and all-cause mortality in patients with diabetes [6].”
BackgroundHanefeld, M., Fleischmann, H., Schiffhorst, G., & Bramlage, P. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0246 · Cited by 21
“…propensity of high insulin doses to increase weight and provoke episodes of severe hypoglycemia: weight gain was 1.6kg in the ORI-GIN study, 4 2.0kg in the ACCORD study, 13 and 8.2kg in the VADT study 14 and was neutral in the ADVANCE study 15 ( - 0.1kg) over several years of follow-up.”
Lee, E. K. P. (2015) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2015.10.001 · Cited by 20
Mooradian, A. D. (2016) · Drugs · doi:10.1007/s40265-016-0609-9 · Cited by 22
Satisfaction with Health Services among the Citizens of Serbia
Mihailović, N., Kocic, S. S., Trajković, G., & Jakovljević, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00050 · Cited by 20
Mantovani, A., Grani, G., Chioma, L., Vancieri, G., Giordani, I., Rendina, R., Rinaldi, M. E., Andreadi, A., Coccaro, C., Boccardo, C., et al. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.004 · Cited by 19
“For the clinicians, reaching a tight glycemic control is often an important goal to minimize the development and progression of chronic complications in many patients with type 1 or type 2 diabetes but, as also highlighted by recent clinical trials, many doubts remain regarding the ‘optimal’ glycemic targets in older…”
BackgroundXu, D., Chandler, O., Wee, C., Ho, C. L. B., Affandi, J. S., Yang, D.-Y. D., Liao, X., Chen, W., Li, Y., Reid, C. M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.712671 · Cited by 22
“Chinese data has echoed the UK findings that 30% of diabetic patients have cardiovascular events, (61) with these events accounting for 20% of diabetes mortality in China (62).”
BackgroundFrailty and Safety: The Example of Diabetes
Abbatecola, A. M., Olivieri, F., Corsonello, A., Strollo, F., Fumagalli, A., & Lattanzio, F. (2012) · Drug Safety · doi:10.1007/bf03319104 · Cited by 22
The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction
Trevisan, R. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0302-3 · Cited by 21
“In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, where patients with T2DM were treated intensively for their condition, hypoglycemic episodes were significantly higher, and this could have contributed to the higher mortality rates observed [8].”
BackgroundLi, S., Wu, H., Han, D. H., Zhang, M., Li, N., Yu, W., Sun, D., Sun, Z., Ma, S., Gao, E., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6451902 · Cited by 20
“Type 2 diabetes is one of the strong independent risk factors for cardiovascular disease and death [1, 2].”
BackgroundThe Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes
Pasquel, F. J., Gregg, E. W., & Ali, M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.11.001 · Cited by 21
Ma, S., Schreiner, P. J., Seaquist, E. R., Ugurbil, M., Zmora, R., & Chow, L. S. (2020) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2020.103379 · Cited by 21
Abdelhamid, Y. A., Bernjak, A., Phillips, L. K., Summers, M. J., Weinel, L. M., Lange, K. M., Chow, E., Kar, P., Horowitz, M., Heller, S. R., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004810 · Cited by 19
“Clinical trials in ambulant patients with type-2 diabetes mellitus (T2DM) have also demonstrated strong associations between treatment-induced hypoglycemia and cardiovascular mortality (3, 4).”
BackgroundJuraschek, S. P., Lipsitz, L. A., Beach, J. L., & Mukamal, K. J. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz015 · Cited by 23
Stidsen, J. V., Nielsen, J. S., Henriksen, J. E., Friborg, S. G., Thomsen, R. W., Olesen, T. B., Olsen, M. H., & Beck‐Nielsen, H. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017493 · Cited by 19
Baas, G., Crutzen, S., Smits, S., Denig, P., Taxis, K., & Heringa, M. (2023) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13931 · Cited by 19
Zhang, Q., Hu, S., Jin, Z., Wang, S., Zhang, B., & Zhao, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1339148 · Cited by 21
The J-Point Phenomenon in Aggressive Therapy of Hypertension: New Insights
Panjrath, G. S., Chaudhari, S., & Messerli, F. H. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0233-4 · Cited by 18
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
Zannad, F. M., Stough, W. G., Pocock, S., Sleight, P., Cushman, W. C., Cleland, J. G. F., McMurray, J. J. V., Lonn, E., Geller, N. L., Wedel, H., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr437 · Cited by 19
“02).(23) The reasons for this mortality increase have been widely debated.”
Zhang, X., Liu, Y., Zhang, F., Li, J., & Tong, N. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.03.015 · Cited by 21
Zhang, W., Liu, C., Ji, L., Wang, J., & For the ATTEND investigators (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13793 · Cited by 19
After avandia: the use of antidiabetic drugs in patients with heart failure.
Khalaf, K. I., & Taegtmeyer, H. (2012) · Europe PMC (PubMed Central) · Cited by 26
Kidney disease: new technologies translate mechanisms to cure
O’Toole, J. F., & Sedor, J. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76825 · Cited by 21
“In addition, landmark clinical trials and observational cohort studies have documented the limitations of current therapies for DKD, showing that further intensification of glycemic and blood pressure control beyond current guidelines does not confer additional benefit and may even cause harm (28, 29).”
Tecilazich, F., Feke, G. T., Mazzantini, S., Sobrin, L., & Lorenzi, M. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18356 · Cited by 18
Updates on medical and surgical managements of diabetic retinopathy and maculopathy
Chen, Y., Radke, N. V., Amarasekera, S., Park, D. H., Chen, N., Chhablani, J. K., Wang, N., Wu, W., Ng, D. S., Bhende, P., et al. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100180 · Cited by 21
Kirsh, S. R., & Aron, D. C. (2011) · Drugs & Aging · doi:10.2165/11594750-000000000-00000 · Cited by 17
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 38
Stuijver, D. J. F., Romualdi, E., van Zaane, B., Bax, L., Buller, H. R., Gerdes, V. E. A., & Squizzato, A. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1168-2 · Cited by 19
Sluik, D., Boeing, H., Montonen, J., Kaaks, R., Lukanova, A., Sandbæk, A., Overvad, K., Arriola, L., Ardanáz, E., Saieva, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038877 · Cited by 19
“Although it is not possible to directly compare achieved HbA1c levels with HbA1c levels observed in a cohort study, these trials have shown that when studying glycemic control, it is important to take into account individual disease characteristics, such as progression, presence of complications and co-morbidities [10…”
BackgroundLemesle, G., Meurice, T., Tricot, O., Lamblin, N., & Bauters, C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008354 · Cited by 19
Kuriyama, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1673-0 · Cited by 17
Pearson, S. M., Whittam, B., Kulavarasalingam, K., Mitchell-Gears, A., James, C., & Ajjan, R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01204-3 · Cited by 21
Tschanz, M. P., Watts, S. A., Colburn, J. A., Conlin, P. R., & POGACH, L. M. (2017) · Europe PMC (PubMed Central) · Cited by 20
Advancements in nanomedicines for the detection and treatment of diabetic kidney disease
Tillman, L., Tabish, T. A., Kamaly, N., Moss, P., El-briri, A., Thiemermann, C., Pranjol, M. Z. I., & Yaqoob, M. M. (2022) · Biomaterials and Biosystems · doi:10.1016/j.bbiosy.2022.100047 · Cited by 19
“Am J Physiol Renal Physiol 2014;306(4):F379–88 .”
BackgroundInfluentialHypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2
Hanefeld, M., Ganz, X., & Nolte, C. (2014) · Herz · doi:10.1007/s00059-014-4086-1 · Cited by 18
Agarwal, S., Parashar, A., & Menon, V. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0070-7 · Cited by 18
Lev, E. I., Singer, J., Leshem‐Lev, D., Rigler, M., Dadush, O., Vaduganathan, M., Battler, A., & Kornowski, R. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313488300 · Cited by 16
“Several studies have shown that maintaining strict glycaemic control in the early stages of diabetes is associated with long-term clinical benefit,(38,39) while others have demonstrated that intensive glycaemic control was associated with increased morbidity, likely related to effects of hypoglycaemia.(40) Another pot…”
BackgroundBenefit–Risk Assessment of Fish Oil in Preventing Cardiovascular Disease
Lands, B. (2016) · Drug Safety · doi:10.1007/s40264-016-0438-5 · Cited by 17
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites
Koshizaka, M., Lópes, R. D., Newby, L. K., Clare, R. M., Schulte, P. J., Tricoci, P., Mahaffey, K. W., Ogawa, H., Moliterno, D. J., Giugliano, R. P., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.030 · Cited by 17
Type 2 diabetes and treatment intensification in primary care in Finland
NISKANEN, L. K., Hahl, J., Haukka, J. K., Leppä, E., Miettinen, T. A., Mushnikov, V., Sipilä, R., Tamminen, N., Vattulainen, P., & Korhonen, P. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1199-7 · Cited by 16
Kazemian, P., Wexler, D. J., Fields, N. F., Parker, R. A., Zheng, A., & Walensky, R. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0393 · Cited by 18
“The model overpredicted (indicated by bold) nonfatal stroke and fatal CHF and underpredicted (indicated by italics) macroalbuminuria and CVD death in ACCORD.”
BackgroundInfluentialAssessment of Insulin Tolerance In Vivo in Mice
Cózar‐Castellano, I., & Perdomo, G. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0385-7_15 · Cited by 18
Kloecker, D. E., Khunti, K., Davies, M. J., Pitocco, D., & Zaccardi, F. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.047 · Cited by 18
The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers
Samaropoulos, X. F., Light, L. S., Ambrosius, W. T., Marcovina, S. M., Probstfield, J. L., & Goff, D. C. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.09.027 · Cited by 19
“As mentioned, multiple medications were used and adjusted for each individual patient in an open label fashion based on the participant’s study-group assignment, therapeutic response to a medication or medication combinations, and development of any adverse effect [19–23].”
BackgroundMethodInfluentialDevelopment and validation of a Health Policy Model of Type 2 diabetes in Chinese setting
Wu, B. Y., Ma, J., Zhang, S., Zhou, L., & Wu, J. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0001 · Cited by 18
Choi, I. J., Choo, E. H., Kim, H. J., Lim, S., Moon, D., Lee, K. Y., Hwang, B., Kim, C. J., Park, M., Lee, J. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01428-x · Cited by 18
“A single study found that intensive control increased mortality [5].”
BackgroundThe new NICE guidelines for type 2 diabetes – a critical analysis
O’Hare, J. P., Millar-Jones, D., Hanif, W., Hicks, D., Evans, M., Leslie, D., Bain, S. C., & Barnett, A. H. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.006 · Cited by 16
Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes
Pillarisetti, S. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.009 · Cited by 15
Managing dyslipidaemia in type 2 diabetes mellitus
Szalat, A., Durst, R. Y., & Leitersdorf, E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.05.004 · Cited by 21
The University Group Diabetes Program 1961-1978: pioneering randomized controlled trial
BLACKBURN, H. W., & Jacobs, D. R. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw168 · Cited by 19
Patoulias, D., Katsimardou, A., Kalogirou, M., Zografou, I., Toumpourleka, M., Imprialos, K. P., Stavropoulos, K., Stergiou, I., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.001 · Cited by 15
Singer, J., Weissler‐Snir, A., Leshem‐Lev, D., Rigler, M., Kornowski, R., & Lev, E. I. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.010 · Cited by 16
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
Zhong, J., Maiseyeu, A., & Rajagopalan, S. (2015) · Clinical Lipidology · doi:10.2217/clp.14.59 · Cited by 16
López, L., Grant, R. W., Marceau, L. D., Piccolo, R. S., McKinlay, J. B., & Meigs, J. B. (2016) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-016-0362-x · Cited by 19
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01347-0 · Cited by 16
Hwang, T. J., Franklin, J., & Kesselheim, A. S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.705 · Cited by 16
Cardiovascular Risk and Sodium–Glucose Cotransporter 2 Inhibition in Type 2 Diabetes
Ingelfinger, J. R., & Rosen, C. J. (2015) · New England Journal of Medicine · doi:10.1056/nejme1512602 · Cited by 15
Packer, M. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004551 · Cited by 16
“Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α(1-67) in patients with type 2 diabetes.”
BackgroundTrained Immunity and Cardiovascular Risk: An Immunological Perspective
Boden, K. A., Chai, J., Kufazvinei, T. T. J., & Choudhury, R. P. (2026) · Immunological Reviews · doi:10.1111/imr.70095 · Cited by 15
Humanism in the time of metrics--an essay by David Loxterkamp
Loxterkamp, D. A. (2013) · BMJ · doi:10.1136/bmj.f5539 · Cited by 17
Sheikh‐Ali, M., Raheja, P., & Borja‐Hart, N. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.01.2621 · Cited by 16
Avoiding hypoglycaemia: a new target of care for elderly diabetic patients
Wong, C. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj144494 · Cited by 17
Luk, A. O. Y., Ho, T. S. T., Lau, E. S. H., Ko, G. T. C., Ozaki, R., Tsang, C.-C., Kong, A. P. S., Ronald, C. W., So, W., Chow, F. C. C., et al. (2016) · Medicine · doi:10.1097/md.0000000000005183 · Cited by 18
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.